Rebecca Lancaster, in Russellville, AR - Clinical Nurse Specialist

Rebecca Lancaster, is a Clinical Nurse Specialist based in Russellville, Arkansas. Rebecca Lancaster is licensed to practice in Arkansas (license number S01010) and her current practice location is 110 Skyline Dr, Russellville, Arkansas. She can be reached at her office (for appointments etc.) via phone at (479) 967-5570.

NPI number for Rebecca Lancaster is 1508076563 and her current mailing address is 110 Skyline Dr, Russellville, Arkansas. She does not participate in medicare program and thus does not accept medicare assignments. Her NPI Number is 1508076563.

Contact Information

	Rebecca Lancaster,
	110 Skyline Dr, Russellville, AR 72801-3362
	(479) 967-5570
	(479) 890-5364

Provider's Profile

Full Name	Rebecca Lancaster
Gender	Female
Speciality	Clinical Nurse Specialist
Location	110 Skyline Dr, Russellville, Arkansas
Accepts Medicare Assignments	Does not participate in Medicare Program. She may not accept medicare assignment.

NPI Data:

NPI Number: 1508076563
Provider Enumeration Date: 05/22/2007
Last Update Date: 07/08/2007

Medical Identifiers

Medical identifiers for Rebecca Lancaster such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1508076563	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
364S00000X	Clinical Nurse Specialist	S01010 (Arkansas)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Rebecca Lancaster is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Rebecca Lancaster, 110 Skyline Dr, Russellville, AR 72801-3362 Ph: (479) 967-5570	Rebecca Lancaster, 110 Skyline Dr, Russellville, AR 72801-3362 Ph: (479) 967-5570

News Archive

InSite Vision commences enrollment in BromSite Phase 3 clinical trial

InSite Vision Incorporated today announced that patient enrollment has begun in the first Phase 3 clinical trial of BromSite (ISV-303) for the reduction of pain and inflammation after cataract surgery.

A new breakthrough for treating nasopharyngeal carcinoma

A team of scientists from the Cancer Science Institute of Singapore (CSI Singapore) at the National University of Singapore, National University Cancer Institute Singapore (NCIS) and National University Hospital Singapore (NUH), discovered a distinct mutational signature and nine significantly mutated genes associated with nasopharyngeal cancer, paving the way to developing novel therapies for this deadly disease.

CTI regains compliance with all applicable NASDAQ listing standards

Cell Therapeutics, Inc. announced that it has received a letter from The NASDAQ Stock Market LLC, indicating that CTI has regained compliance with the minimum bid price rule (i.e., NASDAQ Listing Rule 5550(a)(2)) for continued listing on The NASDAQ Capital Market and that CTI is in compliance with all applicable listing standards.

Scientists reveal origins of second heart field in vertebrates

Using the model organism Ciona intestinalis, commonly known as the sea squirt, researchers at the University of California, Berkeley, have uncovered the origins of the second heart field in vertebrates.

Rebecca Lancaster, - Clinical Nurse Specialist in Russellville, AR